Prevention of uterine bleeding after stem cell transplantation was attempted in 30 consecutive premenopausal women affected by hematological malignancies. This was with luteinizing hormone-releasing hormone (LHRH) leuprorelin acetate depot 3.75 mg administered subcutaneously at least 30 days before the conditioning regimen and then 28 days after the first dose. Complete prevention resulted in all but one patient (96.5%) during the phase of profound thrombocytopenia. No sideeffects related to leuprorelin were observed. All patients developed amenorrhea after transplantation. Gonadal function was periodically assessed by means of luteinizing hormone (LH), follicular stimulating hormone (FSH) and estradiol serum levels. Hormone levels were consistent with menopause in all patients. After transplantation, patients required hormone replacement with estroprogestinics or estrogens alone when indicated. Leuprorelin is highly effective in preventing uterine bleeding in premenopausal women undergoing stem cell transplantation and has an excellent toxicity profile and virtually no interface with hemostatic balance and hepatic function. The role of leuprorelin in gonadal protection is currently unclear and deserves further investigations. Keywords: LHRH analogue; leuprorelin; menstrual bleeding; stem cell transplantation High-dose chemotherapy followed by stem cell transplantation is widely used for treating hematological malignancies and solid tumors. Supportive therapy is crucial for success and for reducing procedure-related toxicity. Uterine bleeding in premenopausal women undergoing myeloablative therapy can be an uncomfortable and troublesome complication. It also increases requirements for blood products and the attendant risks of immunization and infectious complications. Management may be difficult in patients with uterine leyomiomata and severe bleeding, excluding them from an effective anticancer treatment. The classical approach includes use of estroprogestinics which Correspondence: Dr P Salutari, Division of Hematology, Università Cattolica Sacro Cuore, Largo Agostino Gemelli, 8, 00168 Rome, Italy Received 13 August 1997; accepted 13 November 1997 need to be administered by mouth and can influence hemostasis 1 and hepatic function in patients already prone to systemic problems. 2 We investigated the role of leuprorelin, a LHRH analogue, in preventing uterine bleeding in premenopausal women undergoing high-dose chemotherapy and stem cell transplantation. The effect on gonadal function after transplantation was also assessed during follow-up.
High-dose chemotherapy followed by stem cell transplantation is widely used for treating hematological malignancies and solid tumors. Supportive therapy is crucial for success and for reducing procedure-related toxicity. Uterine bleeding in premenopausal women undergoing myeloablative therapy can be an uncomfortable and troublesome complication. It also increases requirements for blood products and the attendant risks of immunization and infectious complications. Management may be difficult in patients with uterine leyomiomata and severe bleeding, excluding them from an effective anticancer treatment. The classical approach includes use of estroprogestinics which Correspondence: Dr P Salutari, Division of Hematology, Università Cattolica Sacro Cuore, Largo Agostino Gemelli, 8, 00168 Rome, Italy Received 13 August 1997; accepted 13 November 1997 need to be administered by mouth and can influence hemostasis 1 and hepatic function in patients already prone to systemic problems. 2 We investigated the role of leuprorelin, a LHRH analogue, in preventing uterine bleeding in premenopausal women undergoing high-dose chemotherapy and stem cell transplantation. The effect on gonadal function after transplantation was also assessed during follow-up.
Patients and methods
Premenopausal women eligible for stem cell transplantation were entered into the trial with leuprorelin. Inclusion criteria were: presence of a hematological malignancy, age Ͻ50 years, anticipated nadir platelet count Ͻ50 × 10 9 /l, no episodes of amenorrhea lasting Ͼ6 months, hormone levels in the non-menopausal range. Informed consent was obtained from all patients or guardians after discussion with the consultant gynecologist. Gonadal function was assessed in all patients pretransplant and during follow-up, by pelvis ultrasound and serum levels of LH, FSH and estradiol.
Thirty patients were entered on the protocol. Median age was 32 years (range 17-45). Eleven patients had acute myelogenous leukemia, seven had Hodgkin's disease, seven had non-Hodgkin's lymphoma, one had chronic myelogenous leukemia, three had acute lymphoblastic leukemia and one had multiple myeloma. Patient characteristics are listed in Table 1 .
Nine patients underwent allogeneic bone marrow transplantation, 15 underwent autologous peripheral blood progenitor cell transplantation and six underwent autologous bone marrow transplantation. Conditioning therapy was busulphan 4 mg/kg p.o. in divided doses daily for 4 days and cyclophosphamide 60 mg/kg once daily for 2 consecutive days (BuCy2) in 21 patients, BuCY2 + ATG in one patient, BEAM in five patients and busulphan 4 mg/kg p.o. in divided doses daily for 4 days and melphalan 90 mg/m 2 (BuMel) in three patients.
Patients received leuprorelin acetate depot 3.75 mg as a subcutaneous injection at least 30 days (range 30-45 days) before conditioning regimen. A second injection was administered 28 days after the first one. No other hormone treatment was permitted within the first 100 days of transplantation. The following endpoints were considered: incidence and duration of vaginal bleeding during the first 100 days after transplantation, incidence of amenorrhea after transplantation and induction of menopausal status after treatment. Side-effects were reported if encountered.
Results
All patients received at least two doses of leuprorelin before transplantation. Ten patients reported menstrual bleeding after the first dose of leuprorelin.
All patients were evaluable for the incidence of menstrual bleeding within the first 100 days after stem cell infusion.
Median duration of severe thrombocytopenia (platelets Ͻ20 × 10 9 /l) was 28 days (range 0-Ͼ100). Only one patient developed menstrual bleeding (96.5% were free of bleeding) during the period of thrombocytopenia after transplantation. This was a 28-year-old patient with chronic myelogenous leukemia who developed hemorrhagic complications at multiple sites during thrombocytopenia with no evidence of disseminated intravascular coagulopathy.
No patient developed vaginal spotting during thrombocytopenia after transplantation. No side-effects were encountered which could be related to leuprorelin administration. There were two early deaths related to GVHD and multiorgan failure, respectively, at day +114 and 109. Twentyeight patients were observed during follow-up for a median of 17 months (range 3-51) and all developed amenorrhea. Hormonal status, assessed regularly at 3, 6 and 12 months after transplantation, was consistent with menopause, with median levels of LH of 40 mIU/ml (range 30-60) FSH 35 mIU/ml (range 30-80), estradiol 15 pg/ml (range 10-25). Only one patient had normal estradiol levels which could be attributed to adrenal production, or to residual ovarian function since she was the youngest patient undergoing stem cell transplantation. Nine patients are already receiving hormone replacement therapy with cyclic estroprogestinics or transdermic estrogen, seven patients did not start treatment because of disease recurrence and death at a median of 10 months (range 4-20) after transplantation. Three patients are not receiving hormone replacement due to concurrent hepatic chronic GVHD. Two patients are lost to follow-up. Eight patients are under evaluation for hormone replacement therapy.
One patient developed deep venous thrombosis during treatment with estroprogesterones as hormone replacement, 1 year after transplantation. This patient was discovered to be an heterozygote for factor II G20210A mutation 3 by PCR analysis.
Discussion
Complications after high-dose chemotherapy and/or radiotherapy relate to profound pancytopenia, mucosal damage and immunosuppressive treatment. Menstrual bleeding is a common complication in premenopausal women during the profound and long-lasting thrombocytopenia. Before the introduction of LHRH agonists, treatment of uterine bleeding invariably included the use of oral contraceptives.
Estroprogestinics, although capable of inducing amenorrhea, require oral administration. There may be poor compliance after chemotherapy and erratic absorption in patients with mucositis and diarrhea. 4 Estroprogestinics may also induce liver toxicity (primarily intrahepatic cholestasis and transaminitis) and they may also interfere with hemostasis 1 through a reduction in the natural anticoagulant, protein S, and an increase in factor II levels. These modifications induce a thrombophilic state which may be further amplified by genetically determined prothrombotic defects which occur fairly commonly in the general population and include activated protein C resistance related to factor V Leiden, or antithrombin III deficiency. 5 Thus, the use of estroprogestinics after stem cell transplantation may increase the risks of toxicity in patients already prone to metabolic complications and they may play a role in the development of veno-occlusive disease after transplantation.
Conversely, LHRH analogues which induce amenorrhea secondary to suppression of the pituitary-gonadal axis 6 do not interfere with the hemostatic system 7 and do not cause hepatic damage. Side-effects after prolonged treatment are mild and related to a profound and transient hypoestrogenemia. In a review by Fogelman 8 a decrease in bone mineral density is well documented in females receiving LHRH; within 3 months of eliminating the protective effect of estrogen on the skeleton, there is a rise in serum parameters, reflecting an increase in bone resorption and bone formation. As demonstrated by other authors and by us in previous studies, LHRH analogues are effective and safe for prevention of menstrual bleeding in women with hematological malignancies at the onset of their disease or after stem cell transplantation. [9] [10] [11] [12] The mechanism of action of LHRH analogues is characterized by two phases: first, they stimulate follicular maturation and then, by binding to specific receptors, they prevent stimulation by a negative feedback effect on the pituitary gland. Some patients may therefore develop menstrual bleeding immediately after LHRH analogue administration depending upon the stage of the menstrual cycle at which the drug was introduced. It is therefore recommended that leuprorelin is not introduced in the immediate vicinity of chemotherapy to prevent additional toxicity on the ovaries stimulated by LHRH.
However, leukemia patients with active vaginal bleeding at the onset of their disease treated with leuprorelin at the beginning of the induction chemotherapy resumed normal ovarian function after chemotherapy and retained it up to transplantation. 12 In the present study a very low dose of the LHRH analogue leuprorelin (3.75 mg) in a slow release formulation, given at least 30 days before the conditioning regimen and repeated 28 days after the first dose, completely prevented menstrual bleeding during the period of thrombocytopenia. Furthermore, this schedule reduces exposure to unnecessary and expensive high doses of LHRH analogues as reported initially by other authors. [9] [10] [11] Compliance was optimal with virtually no short-term side-effects. As a result of protract leuprorelin administration a decrease in uterine volume has been observed 13 and treatment with LHRH analogues should also be recommended for women with uterine leyomiomata or dysfunctional bleeding eligible for stem cell transplantation for whom surgery is not indicated or requires delay. 14 Based on their action on the pituitary-gonadal axis, the use of LHRH analogues for gonadal protection has been suggested. Several investigators have suggested that inhibition of gametogenesis might reduce or even eliminate treatmentinduced gonadal injury 15 but there is no general consensus on this matter. In our study we failed to demonstrate any beneficial effect on gonadal function since early menopause was the norm in our patients. In fact only one patient showed any sex hormone production after transplantation; she is 17 years old and her young age may account for the residual ovarian activity. The high incidence of menopause in this series is partly related to the use of busulfan-containing conditioning therapy and to the age of patients recruited into the study; the schedule of LHRH used in this study should not contribute to ovarian toxicity. In a recent review from Sanders et al 16 only one out of 73 women recovered ovarian function after high-dose busulfan.
Cyclic hormone replacement still remains the optimal treatment for younger patients unless clinically contraindicated. A detailed coagulation screen encompassing the recently recognized inherited or acquired thrombophilic parameters should be mandatory in these patients before long-term hormone replacement is instituted in order to avoid thromboembolic complications.
